MNLO - Menlo Therapeutics Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.3450
+0.0050 (+0.12%)
As of 12:32PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.3400
Open4.3000
Bid4.3300 x 800
Ask4.3600 x 800
Day's Range4.2600 - 4.3700
52 Week Range3.7400 - 11.9990
Volume7,143
Avg. Volume51,024
Market Cap104.001M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.4970
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.80
Trade prices are not sourced from all markets
  • Did You Manage To Avoid Menlo Therapeutics's (NASDAQ:MNLO) 42% Share Price Drop?
    Simply Wall St.23 hours ago

    Did You Manage To Avoid Menlo Therapeutics's (NASDAQ:MNLO) 42% Share Price Drop?

    It's easy to match the overall market return by buying an index fund. But if you buy individual stocks, you can do...

  • CNW Group4 days ago

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

    Life Science Company Live Investor Presentations Now Available for On-Demand Viewing

  • PR Newswire10 days ago

    Life Science Company Live Investor Conference July 11th

    Life science company executives will share vision and answer audience questions at VirtualInvestorConferences.com NEW YORK , July 9, 2019 /PRNewswire/ -- Virtual Investor Conferences today announced the ...

  • Is Menlo Therapeutics Inc. (MNLO) A Good Stock To Buy ?
    Insider Monkey20 days ago

    Is Menlo Therapeutics Inc. (MNLO) A Good Stock To Buy ?

    A market surge in the first quarter, spurred by easing global macroeconomic concerns and Powell's pivot ended up having a positive impact on the markets and many hedge funds as a result. The stocks of smaller companies which were especially hard hit during the fourth quarter slightly outperformed the market during the first quarter. Unfortunately, […]

  • GlobeNewswirelast month

    Menlo Therapeutics Announces Addition of Ronald A. Krasnow as General Counsel and Chief Compliance Officer

    REDWOOD CITY, Calif., June 18, 2019 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the.

  • GlobeNewswire2 months ago

    Menlo Therapeutics to Present at Upcoming Investor Conferences

    The presentations will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • GlobeNewswire2 months ago

    EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

    To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (MNLO) pursuant or traceable to the Company’s Initial Public Offering closed on January 29, 2018. If you purchased or otherwise acquired Menlo securities pursuant to the initial public offering, your rights may be affected by this action. In its January 2018 IPO, Menlo issued over 8 million shares at $17 per share, raising over $136 million in gross proceeds.

  • GlobeNewswire3 months ago

    Menlo Therapeutics to Present at the Class of 2018 Biotech IPOs Investor Day

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Steve Basta, Chief Executive Officer, will present at the Class of 2018 Biotech IPOs Investor Day on Friday April 26, 2018 at 11:00 a.m. ET in New York, New York. The presentation will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus.

  • Consider These 3 Falling Knives
    GuruFocus.com3 months ago

    Consider These 3 Falling Knives

    Wall Street issued a buy recommendation rating for all three stocks, increasing the likelihood of them outperforming the S&P 500 Index over the next 52 weeks. Warning! GuruFocus has detected 2 Warning Sign with CTMX. Further, these companies have a GuruFocus financial strength rating of at least 5 out of 10, reducing the bankruptcy rate risk, which is quite common among falling knives.

  • GlobeNewswire4 months ago

    Menlo Therapeutics Announces Publication of Serlopitant Phase 2 Data for the Treatment of Pruritus Associated with Prurigo Nodularis

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced the publication of the company’s Phase 2 trial of serlopitant for the treatment of pruritus associated with prurigo nodularis (PN) in the Journal of the American Academy of Dermatology (JAAD). In this randomized, double-blind, placebo-controlled study, 128 patients with chronic, treatment-refractory PN for more than 6 weeks received serlopitant, 5 mg, or placebo orally once daily for 8 weeks.

  • GlobeNewswire4 months ago

    Menlo Therapeutics Announces New Board Member Elisabeth Sandoval

    Menlo Therapeutics Inc. (MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus (itch), today announced that Elisabeth Sandoval has been appointed as a member of Menlo’s Board of Directors, effective immediately.  Ms. Sandoval currently serves as Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, previously served as Chief Commercial Officer of KYTHERA Biopharmaceuticals, and prior to that role, as Vice President of Global Marketing for Allergan. In addition to her responsibilities as Chief Commercial Officer and Executive Vice President of Corporate Strategy for Alder Biopharmaceuticals, a clinical stage company focused on developing novel therapeutic antibodies for the treatment of migraine, Ms. Sandoval is also responsible for developing and leading the company’s medical affairs, investor relations, corporate communications and business development functions.  Before joining Alder, she was Chief Commercial Officer for KYTHERA Biopharmaceuticals, where she led the commercial strategy and execution including the hiring and development of all commercial functions and launch of a first-in-class product prior to KYTHERA’s acquisition by Allergan.

  • GlobeNewswire4 months ago

    Menlo Therapeutics to Present at the 31st Annual ROTH Conference

    The presentation will be webcast live and can be accessed by logging onto the “Investors” section of the Menlo Therapeutics website, www.menlotherapeutics.com, prior to the event. Menlo Therapeutics Inc. is a late-stage biopharmaceutical company focused on the development of serlopitant, a once-daily oral NK1 receptor antagonist, for the treatment of pruritus. The company’s clinical development program for serlopitant includes two ongoing Phase 3 clinical trials for the treatment of pruritus associated with prurigo nodularis, a planned Phase 3 program for the treatment of pruritus associated with psoriasis, and a Phase 2 clinical trial for the treatment of chronic pruritus of unknown origin.

  • GlobeNewswire5 months ago

    Menlo Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

    “We are making solid progress in the clinical development of serlopitant for pruritus associated with prurigo nodularis (PN), our most advanced indication.  Both Phase 3 PN trials are enrolling well, and we expect results from these trials in the first half of 2020,” stated Steve Basta, Chief Executive Officer of Menlo Therapeutics.  “If our PN trials are successful, we expect to file an NDA for our first indication in 2020.

  • GlobeNewswire5 months ago

    INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Menlo Therapeutics, Inc. of Class Action Lawsuit

    To: All persons or entities who purchased or otherwise acquired securities of Menlo Therapeutics, Inc. (“Menlo” or the “Company”) (MNLO) pursuant or traceable to the Company’s Initial Public Offering closed on January 29, 2018. If you purchased or otherwise acquired Menlo securities pursuant to the initial public offering, your rights may be affected by this action. In its January 2018 IPO, Menlo issued over 8 million shares at $17 per share, raising over $136 million in gross proceeds.

  • GlobeNewswire6 months ago

    Menlo Therapeutics Announces Late-Breaking Oral Presentation at the American Academy of Dermatology Annual Meeting

    The abstract, “Serlopitant Reduced Pruritus Associated with Psoriasis in Phase 2 Randomized, Double-Blind, Placebo-Controlled Clinical Trial” will be presented as part of Late Breaking Research: Clinical Trials on Saturday, March 2 between 1:00 p.m. and 4:00 p.m. in Ballroom A. In addition, a second abstract, “Improvement of Itch and Pain in Patients with Prurigo Nodularis Treated with Serlopitant: Secondary analysis of Phase 2 Clinical Trial” was accepted as an oral presentation and online e-poster.  Presentations will be held on Friday, March 1 and Saturday, March 2.

  • GlobeNewswire6 months ago

    Report: Developing Opportunities within Incyte, Burlington Stores, Hannon Armstrong Sustainable Infrastructure Capital, iRobot, Lear, and Menlo Therapeutics — Future Expectations, Projections Moving into 2019

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • GlobeNewswire6 months ago

    Menlo Therapeutics’ Serlopitant Granted Breakthrough Therapy Designation by FDA for the Treatment of Pruritus Associated with Prurigo Nodularis

    REDWOOD CITY, Calif., Jan. 15, 2019 -- Menlo Therapeutics Inc. (NASDAQ: MNLO), a late-stage biopharmaceutical company focused on the development of serlopitant for the.

  • GlobeNewswire6 months ago

    Lawsuit for Investors in NASDAQ: MNLO shares against Menlo Therapeutics Inc. announced by Shareholders Foundation

    In January 2018, Menlo Therapeutics Inc. (MNLO) completed its IPO, selling over 8 million shares of common stock at $17.00 per share. The plaintiff claims that in its registration statement, Menlo Therapeutics Inc. stated that if the results of its Phase 2 clinical trials for the treatment of pruritus are promising, the company would "rapidly advance into Phase 3 clinical trials" and would use the net proceeds from the IPO to fund such trials.

  • What does Menlo Therapeutics Inc.’s (NASDAQ:MNLO) Balance Sheet Tell Us About Its Future?
    Simply Wall St.6 months ago

    What does Menlo Therapeutics Inc.’s (NASDAQ:MNLO) Balance Sheet Tell Us About Its Future?

    Menlo Therapeutics Inc. (NASDAQ:MNLO), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is MNLO Read More...

  • ACCESSWIRE7 months ago

    Lawsuit for Investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) announced by Shareholders Foundation

    SAN DIEGO, CA / ACCESSWIRE / December 17, 2018 / The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain investors in shares of Menlo Therapeutics Inc. (NASDAQ: MNLO) over alleged ...

  • Menlo Therapeutics Inc. (MNLO): Are Hedge Funds Right About This Stock?
    Insider Monkey7 months ago

    Menlo Therapeutics Inc. (MNLO): Are Hedge Funds Right About This Stock?

    Is Menlo Therapeutics Inc. (NASDAQ:MNLO) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access […]